Treating Bone Disease Improves Myeloma Outcomes
All patients with myeloma should be treated for bone disease.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care